Advertisement Formpipe Announces Interim Report January - June 2014 - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
More info about

Formpipe Announces Interim Report January – June 2014

Period 1 January – 30 JUNE 2014

  • Net sales SEK 163.3m (SEK 139.8m)
  • System revenue SEK 104.2m (SEK 94.7m)
  • EBITDA SEK 31.8m (SEK 25.2m)
  • EBITDA margin 19.5% (18.1%)
  • EBIT 11.3m (SEK 7.2m)
  • Net profit SEK 5.8m (SEK 2.3m)
  • EPS before dilution SEK 0.11 (SEK 0.04)
  • Cash flow from operating activities SEK 22.6m (SEK 27.3m)

Period 1 April – 30 June 2014

  • Net sales SEK 84.2m (SEK 72.6m)
  • System revenue SEK 54.7m (SEK 48.6m)
  • EBITDA SEK 16.6m (SEK 13.1m)
  • EBITDA margin 19.7% (18.0%)
  • EBIT 6.0m (SEK 4.0m)
  • Net profit SEK 3.0m (SEK 1.9m)
  • EPS before dilution SEK 0.05 (SEK 0.03)
  • Cash flow from operating activities SEK 7.8m (SEK 7.2m)